Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich’s ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Financial Outlook | Cash runway into 2026 supports clinical progress, with analyst price targets ranging from $15 to $16, despite current market volatility |
Expanding Horizons | FDA clearance for SGT-212 in Friedreich's ataxia marks significant pipeline expansion, addressing both neurologic and cardiac manifestations |
DMD Breakthrough | SGT-003 for Duchenne muscular dystrophy enters Phase 1/2 trials, promising potential superiority over first-generation therapies |
Gene Therapy Pionee | Solid Biosciences leads in AAV-based gene therapies for DMD and FA, with innovative approaches to transgene optimization and capsid design |
Metrics to compare | SLDB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLDBPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −5.8x | −0.6x | |
PEG Ratio | −0.03 | 0.04 | 0.00 | |
Price / Book | 0.8x | 2.3x | 2.6x | |
Price / LTM Sales | - | 31.9x | 3.1x | |
Upside (Analyst Target) | 365.1% | 142.1% | 48.7% | |
Fair Value Upside | Unlock | 6.1% | 7.7% | Unlock |